Development of immune checkpoint inhibitors, such as anti-CTLA-4, anti-PD-1 and anti-PD-L1, bypass the immune checkpoint, with the aim of rescuing and enhancing the function of anti-tumor T cells [19]. This evidence concerns the gene PDCD1 and neoplasm.